For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of this treatment and Attruby represents a true advancement . These innovative therapies stabilize the transthyretin protein, slowing its destructive build-up and reducing the burden